Navigation Links
Renhuang Announces Fiscal Year 2010 Guidance

HARBIN, China, March 4 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced revenue and net income guidance for fiscal year 2010 ("FY 2010") ending October 31, 2010.

Renhuang expects revenues for FY 2010 to be in the range of $54.7-$55.6 million, which represents a 26% to 28% increase over reported revenues of $43.4 million in fiscal year 2009. The Company expects FY 2010 net income to be in the range of $18.6-$18.9 million, up 26% to 28% from net income of $14.8 million in fiscal year 2009.

"We anticipate strong organic growth in the top- and bottom-line to be driven by our continued focus on higher margin product offerings and expanding our direct sales efforts," commented Mr. Shaoming Li, Renhuang's chairman and CEO. "As the leading supplier of Siberian Ginseng (Acanthopanax)-based products and with an extensive nationwide distribution network, we are confident in our ability to capitalize on China's rapidly growing pharmaceutical market and continue our track record of delivering robust growth. In addition, positive financial growth in the first quarter of fiscal 2010 strengthens our confidence in meeting our guidance for fiscal year 2010."

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, bio-pharmaceutical products, and botanical antibiotic and OTC TCMs through its extensive distribution network of over 3,000 distributors and more than 70 sales centers across 24 provinces in China.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand and market acceptance of the Company's products, the Company's ability to meet its financial guidance, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-5392-5461

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Phone: +1-646-833-3417 (New York)

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)

SOURCE Renhuang Pharmaceuticals, Inc.

Back to top



SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), ... Contract Manufacturing, and iForce Nutrition ("iForce"), one of the ... United States , today announced that they ... Hi-Tech has agreed to acquire iForce. The transaction ... expand its distribution through iForce,s strong distribution network. ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) ... 50 new jobs to its research and development presence at ... New York . --> ... include a translational immuno-oncology hub and a Lilly "portal," which ... to cutting-edge drug discovery capabilities, including chemistry and lead optimization ...
(Date:10/9/2015)... 9, 2015 Ansun BioPharma announced a presentation ... America ) regarding the compassionate use of DAS181 under ... respirator who was co-infected with influenza and parainfluenza (Abstract ... therapy, O 2 requirement was reduced and the ... to go off the respirator on day 5. Between ...
Breaking Medicine Technology:
... MINNEAPOLIS, Jan. 19, 2012 Zyga Technology, Inc. announced ... the company and will serve as Vice President of ... (Logo: ) Joe ... Medical Device Industry.  He began his career at Codman ...
... Berkery Noyes, an independent middle market investment bank, today ... trend report for the Pharma & Healthcare ... report analyzes the sector for 2011 and compares it ... includes information and technology companies servicing pharmaceutical, healthcare payer, ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT ... product specifications for TRACTUS, the world’s first sterile field scanner. , ... response to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation of America (AAFA) ... and Prevention (CDC) to improve the knowledge and skills of underserved adults with asthma. ... project by the CDC and allows AAFA to continue vital efforts to educate people ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, a ... is initiating a combined charity effort with Animal Rescue New Orleans in an ... , Animal Rescue New Orleans is a non-profit organization committed to rescuing ...
(Date:10/9/2015)... ... 2015 , ... Prescription Hope, the fastest growing pharmacy program ... save money on the high cost of their prescription medications through their pharmacy ... families can receive their medications delivered direct from over 180 U.S.-based pharmaceutical manufacturers. ...
(Date:10/9/2015)... City, UT (PRWEB) , ... October 09, 2015 , ... ... Mental Illness Awareness Week. For many teenagers facing mental illness, the stigma associated with ... they need. , ViewPoint Center understands the importance of supporting teens with ...
Breaking Medicine News(10 mins):
... a significant decrease in the function of the serotonin system ... that regulates such functions as impulse control and mood. It ... men. This is the conclusion of multidisciplinary research carried out ... the University of Gothenburg, Sweden. The research group in ...
... , TUESDAY, Nov. 15 (HealthDay News) -- ,Elite female marathon ... and sedentary women, a new study finds. This type ... the most common type of heart disease and the leading ... recent Minneapolis Heart Institute study found that elite male marathoner ...
... specific community-based screening may increase awareness of the dangers of ... in the November 2011 issue of Otolaryngology-Head and Neck ... 60 to 80% of head and neck cancers could be ... national programs to date have had little impact reducing these ...
... Human pluripotent stem cells, which can develop into any ... or sugar fermentation, to drive their metabolic activities. ... depend more on cell mitochondria to convert sugar and ... energy-producing process called oxidative phosphorylation for their metabolic needs. ...
... clear links between erectile dysfunction (ED) and peripheral neuropathy, according ... journal BJUI . "Up to now the impact ... has been underestimated" says lead author Dr Consuelo ,Valles-Antua, from ... Asturias in Oviedo. "However our study of 90 ...
... HealthDay Reporter , MONDAY, Nov. 14 (HealthDay News) ... contraceptive pill over the past 40 years, the amount of ... the increased incidence of prostate cancer around the world, Canadian ... cancers, and the widespread use of the pill might raise ...
Cached Medicine News:
Adsons bayonet forceps....
Rees bayonet forceps, standard, 5-1/2", TC....
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
... Implants, designed to accept rigid ... with an excellent reconstructive option ... floor blowout defects. Each design ... of one or more rigid ...
Medicine Products: